Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology

22-04-2024 | Gastric Cancer | JSCO Board of Directors Series

Biomarker-oriented chemo-immunotherapy for advanced gastric cancer

Authors: Koji Kono, Shotaro Nakajima, Kosaku Mimura

Published in: International Journal of Clinical Oncology

Login to get access

Abstract

The biomarker-oriented chemo-immunotherapy is useful and promising in the development of new anticancer agents, since the responders can be enriched by selecting patients with biomarkers. Compared to colorectal and lung cancers, the development of biomarker-driven molecular-targeted therapeutics for gastric cancers has been straggled. However, several new biomarkers in gastric cancers have been discovered and clinical trials in enrichment design with certain biomarkers have been conducted. Therefore, there are currently several treatment options to treat gastric cancer patients based on individual biomarker-oriented strategies. In the present review, we describe the useful biomarkers in gastric cancer, with focusing on HER2, PD-L1, and Claudin18.2, in relation to their clinical significance and associated targeted agents.
Literature
1.
Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249PubMedCrossRef
2.
Japanese Gastric Cancer Association (2017) Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 20:1–19CrossRef
3.
Sasako M, Sakuramoto S, Katai H et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387–4393PubMedCrossRef
4.
5.
Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221PubMedCrossRef
6.
Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697PubMedCrossRef
7.
Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31–39PubMedCrossRef
8.
Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224–1235PubMedCrossRef
9.
10.
11.
12.
13.
Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461–2471PubMedCrossRef
14.
Muro K, Chung HC, Shankaran V et al (2016) Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 17:717–726PubMedCrossRef
15.
Shitara K, Fleitas T, Kawakami H et al (2024) Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. ESMO Open 9:102226PubMedPubMedCentralCrossRef
16.
Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202–209CrossRef
17.
18.
Wainberg ZA, Enzinger PC, Kang YK et al (2022) Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 23:1430–1440PubMedCrossRef
19.
Shitara K, Lordick F, Bang YJ et al (2023) Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401:1655–1668PubMedCrossRef
20.
Shah MA, Shitara K, Ajani JA et al (2023) Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 29:2133–2141PubMedPubMedCentralCrossRef
21.
Janjigian YY, Kawazoe A, Bai Y et al (2023) Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet 402:2197–2208PubMedCrossRef
22.
Van Cutsem E, Bang YJ, Feng-Yi F et al (2015) HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18:476–484PubMedCrossRef
23.
Cancer Genome Atlas Research Network (2017) Integrated genomic characterization of oesophageal carcinoma. Nature 541:169–175CrossRef
24.
Fukai S, Nakajima S, Saito M et al (2023) Down-regulation of stimulator of interferon genes (STING) expression and CD8(+) T-cell infiltration depending on HER2 heterogeneity in HER2-positive gastric cancer. Gastric Cancer 26:878–890PubMedCrossRef
25.
Kurokawa Y, Sugimoto N, Miwa H et al (2014) Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer 110:1163–1168PubMedPubMedCentralCrossRef
26.
Miura Y, Sukawa Y, Hironaka S et al (2018) Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G). Gastric Cancer 21:84–95PubMedCrossRef
27.
Ryu MH, Yoo C, Kim JG et al (2015) Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer 51:482–488PubMedCrossRef
28.
Takahari D, Chin K, Ishizuka N et al (2019) Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer. Gastric Cancer 22:1238–1246PubMedCrossRef
29.
Makiyama A, Sukawa Y, Kashiwada T et al (2020) Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study). J Clin Oncol 38:1919–1927PubMedCrossRef
30.
Satoh T, Xu RH, Chung HC et al (2014) Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN–a randomized, phase III study. J Clin Oncol 32:2039–2049PubMedCrossRef
31.
Tabernero J, Hoff PM, Shen L et al (2018) Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol 19:1372–1384PubMedCrossRef
32.
Thuss-Patience PC, Shah MA, Ohtsu A et al (2017) Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol 18:640–653PubMedCrossRef
33.
Ogitani Y, Aida T, Hagihara K et al (2016) DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 22:5097–5108PubMedCrossRef
34.
Ogitani Y, Hagihara K, Oitate M et al (2016) Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci 107:1039–1046PubMedPubMedCentralCrossRef
35.
Shitara K, Bang YJ, Iwasa S et al (2020) Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 382:2419–2430PubMedCrossRef
36.
Janjigian YY, Maron SB, Chatila WK et al (2020) First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol 21:821–831PubMedPubMedCentralCrossRef
37.
Lee CK, Rha SY, Kim HS et al (2022) A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer. Nat Commun 13:6002PubMedPubMedCentralCrossRef
38.
Togasaki K, Sukawa Y, Kanai T et al (2018) Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies. Onco Targets Ther 11:8239–8250PubMedPubMedCentralCrossRef
39.
Wang W, Sun J, Li F et al (2012) A frequent somatic mutation in CD274 3’-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding. Hum Mutat 33:480–484PubMedCrossRef
40.
Wang W, Li F, Mao Y et al (2013) A miR-570 binding site polymorphism in the B7–H1 gene is associated with the risk of gastric adenocarcinoma. Hum Genet 132:641–648PubMedCrossRef
41.
Zerdes I, Matikas A, Bergh J et al (2018) Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene 37:4639–4661PubMedPubMedCentralCrossRef
42.
Oki E, Okano S, Saeki H et al (2017) Protein expression of programmed death 1 ligand 1 and HER2 in gastric carcinoma. Oncology 93:387–394PubMedCrossRef
43.
Menyhárt O, Pongor LS, Győrffy B (2018) Mutations defining patient cohorts with elevated PD-L1 expression in gastric cancer. Front Pharmacol 9:1522PubMedCrossRef
44.
Taube JM, Anders RA, Young GD et al (2012) Colocalization of inflammatory response with B7–h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4:127ra137CrossRef
45.
Mimura K, Teh JL, Okayama H et al (2018) PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci 109:43–53PubMedCrossRef
46.
Moon JW, Kong SK, Kim BS et al (2017) IFNgamma induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma. Sci Rep 7:17810PubMedPubMedCentralCrossRef
47.
Zhou KI, Peterson B, Serritella A et al (2020) Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin Cancer Res 26:6453–6463PubMedPubMedCentralCrossRef
48.
Nakajima S, Mimura K, Kaneta A et al (2023) Radiation-induced remodeling of the tumor microenvironment through tumor cell-intrinsic expression of cGAS-STING in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 115:957–971PubMedCrossRef
49.
Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27–40PubMedPubMedCentralCrossRef
50.
Janjigian YY, Ajani JA, Moehler M et al. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol 2024;JCO2301601
51.
Kang YK, Chen LT, Ryu MH et al (2022) Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23:234–247PubMedCrossRef
52.
Rha SY, Oh DY, Yanez P et al (2023) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 24:1181–1195PubMedCrossRef
53.
54.
Sahin U, Koslowski M, Dhaene K et al (2008) Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 14:7624–7634PubMedCrossRef
55.
56.
57.
Pellino A, Brignola S, Riello E et al (2021) Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J Pers Med 11:1095PubMedPubMedCentralCrossRef
58.
Kubota Y, Kawazoe A, Mishima S et al (2023) Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open 8:100762PubMedPubMedCentralCrossRef
59.
Rohde C, Yamaguchi R, Mukhina S et al (2019) Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Jpn J Clin Oncol 49:870–876PubMedPubMedCentralCrossRef
60.
Coati I, Lotz G, Fanelli GN et al (2019) Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. Br J Cancer 121:257–263PubMedPubMedCentralCrossRef
61.
Inamoto R, Takahashi N, Yamada Y (2023) Claudin18.2 in advanced gastric cancer. Cancers (Basel) 15:5742PubMedCrossRef
62.
63.
Lordick F, Thuss-Patience P, Bitzer M et al (2023) Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer. J Cancer Res Clin Oncol 149:5937–5950PubMedPubMedCentralCrossRef
64.
Konno H, Lin T, Wu R et al (2022) ZL-1211 exhibits robust antitumor activity by enhancing ADCC and activating NK cell-mediated inflammation in CLDN18.2-high and -low expressing gastric cancer models. Cancer Res Commun 2:937–950PubMedPubMedCentralCrossRef
65.
Davenport AJ, Jenkins MR, Cross RS et al (2015) CAR-T cells inflict sequential killing of multiple tumor target cells. Cancer Immunol Res 3:483–494PubMedCrossRef
66.
Upadhyay R, Boiarsky JA, Pantsulaia G et al (2021) A critical role for fas-mediated off-target tumor killing in T-cell immunotherapy. Cancer Discov 11:599–613PubMedCrossRef
67.
Botta GP, Kelly RJ, Jin Z et al (2024) CLDN18.2 chimeric antigen receptor T cell therapy for patients with advanced gastric and pancreatic adenocarcinoma: results of ELIMYN18.2 phase 1b clinical trial. J Clin Oncol 42:356CrossRef
68.
Wang YGJ, Lin R, Zhao S et al (2023) First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors. J Clin Oncol 41:3016CrossRef
69.
Fuchs CS, Doi T, Jang RW et al (2018) Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 4:e180013PubMedPubMedCentralCrossRef
70.
Shitara K, Özgüroğlu M, Bang YJ et al (2018) Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 392:123–133PubMedCrossRef
71.
Kim ST, Cristescu R, Bass AJ et al (2018) Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 24:1449–1458PubMedCrossRef
72.
Yearley JH, Gibson C, Yu N et al (2017) PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res 23:3158–3167PubMedCrossRef
73.
Tanegashima T, Togashi Y, Azuma K et al (2019) Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity. Clin Cancer Res 25:4808–4819PubMedCrossRef
74.
Ohigashi Y, Sho M, Yamada Y et al (2005) Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11:2947–2953PubMedCrossRef
75.
76.
Nakayama Y, Mimura K, Tamaki T et al (2019) Phospho-STAT1 expression as a potential biomarker for anti-PD-1/anti-PD-L1 immunotherapy for breast cancer. Int J Oncol 54:2030–2038PubMedPubMedCentral
77.
Nakayama Y, Mimura K, Kua LF et al (2020) Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer. Gastric Cancer 23:961–973PubMedCrossRef
Metadata
Title
Biomarker-oriented chemo-immunotherapy for advanced gastric cancer
Authors
Koji Kono
Shotaro Nakajima
Kosaku Mimura
Publication date
22-04-2024
Publisher
Springer Nature Singapore
Published in
International Journal of Clinical Oncology
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-024-02525-z
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits